Biologics as treatment for systemic lupus: Great efforts, sobering results, new challenges

Current Drug Discovery Technologies

Volumn 6, Issue 4, 2009, Pages 252-255

  Schröder, Johann O ^a   Zeuner, Rainald A ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Biologics; Clinical trials; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; AUTOANTIBODY; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPRATUZUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; MEDI 545; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449727689     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789869010     Document Type: Review

References (25)

1. Schroeder JO, Euler HH. Recognition and managment of systemic lupus erythematosus. Drugs 1997; 54(3): 422-434 (Pubitemid 27395592)
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9): 929-939
3. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 1988; 331(6154): 356-358
4. Ramos-Casals M, Brito-Zerón P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86(4): 242-251 (Pubitemid 47067483)
5. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50(19): 3161-3169 (Pubitemid 39371992)
6. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009. [Epub ahead of print].
7. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4lg and cyclophosphamide. J Immunol 2001; 166(5): 2913-2916 (Pubitemid 33117284)
8. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. N Engl J Med 2003; 349(20): 1907-1915 (Pubitemid 37409707)
9. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti- CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8(3): R74.
10. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61(9): 1168-1178
11. Isenberg D, Gordon C, Merrill J, et al. New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution. Lupus 2008; 17(11): 967-970
12. Sanz I. The conundrum of B cell depletion in SLE. Nat Rev Rheumatol 2009; 5(6): 304-305
13. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials - an interim analysis. Nat Rev Rheumatol 2009; 5(6): 348-351
14. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314(10): 614-619
15. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46(4): 995-1002. (Pubitemid 34303812)
16. Grootschoten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70(4): 32-42.
17. Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 1994; 21(12): 2239-2241
18. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000; 9(9): 651-654 (Pubitemid 32011789)
19. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8(8): 685-691 (Pubitemid 29520536)
20. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56(9): 3044-3056 (Pubitemid 47502752)
21. Rönnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008; 17: 394-399 (Pubitemid 351798715)
22. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9(9): 664-671 (Pubitemid 32011791)
23. Sigurdsson S, Nordmark G, Göring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76(3): 528-537 (Pubitemid 40250533)
24. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357(24): 2517-2518 (Pubitemid 350272800)
25. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60(6): 1785-1796